secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001193125-24-037521
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics appoints Rajiv Patni as Class III director
--------------------------------------------------------------

- Rajiv Patni appointed to board effective Feb 15, 2024 as Class III director, term through 2025 annual meeting.
- Receives $38,000 annual retainer plus 54,000-share stock option grant under 2019 Equity Incentive Plan.
- Options vest in equal annual installments over 3 years, exercise price equals Feb 15 closing price.
- Entered standard indemnification agreement; no family relationships or related party transactions with company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524037521/0001193125-24-037521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524037521/d791068d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-037521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer